1388727-70-5

Basic information

• Product Name: N-(1-(3-methoxyphenyl)piperazin-1-yl)-(13S)-15-acetoxylabd-8-⁽¹⁷⁾-en-19-methyl ester
• CAS NO: 1388727-70-5
• Molecular Weight: 568.797
• Mol File: 1388727-70-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(1-(3-methoxyphenyl)piperazin-1-yl)-(13S)-15-acetoxylabd-8-⁽¹⁷⁾-en-19-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1-(3-methoxyphenyl)piperazin-1-yl)-(13S)-15-acetoxylabd-8-⁽¹⁷⁾-en-19-methyl ester(1388727-70-5)
• EPA Substance Registry System: N-(1-(3-methoxyphenyl)piperazin-1-yl)-(13S)-15-acetoxylabd-8-⁽¹⁷⁾-en-19-methyl ester(1388727-70-5)

Safety Data

• Hazardous Substances Data: 1388727-70-5(Hazardous Substances Data)

Upstream product

• 4742-38-5 (1S,4aR,5S,8aR)-decahydro-5-[(3S)-5-hydroxy-3-methylpentyl]-1,4a-dimethyl-6-methylenenaphthalene-1-carboxylic acid 
• 5572-85-0 (13S)-15-hydroxylabd-8⁽¹⁷⁾-en-19-methyl ester 

Relevant articles and documents

Synthesis of novel imbricatolic acid analogues via insertion of N-substituted piperazine at C-15/C-19 positions, displaying glucose uptake stimulation in L6 skeletal muscle cells

A new class of N-substituted piperazine analogues of imbricatolic acid have been designed and synthesized by using the appropriate synthetic routes in excellent yield. All synthesised compounds were screened for their in vitro glucose uptake stimulatory activity. Among them compounds 4b, 4e, 8b, and 8e triggered L6 skeletal muscle cells for glucose uptake at 54.73%, 40.79%, 40.90%, and 39.55% stimulation, respectively. Compound 4b has emerged as important lead compound showing potential antidiabetic activity. Illustration about their synthesis and in vitro glucose uptake activity is described.